Vol 94, No 6 (2023)
Research paper
Published online: 2022-08-16

open access

Page views 1848
Article views/downloads 1053
Get Citation

Connect on Social Media

Connect on Social Media

Improving pregnancy rate in infertile patients with polycystic ovarian syndrome receiving clomiphene citrate and cabergoline in euprolactinomic women in single cycle treatment

Suha J. Witwit1
Pubmed: 35984341
Ginekol Pol 2023;94(6):456-462.

Abstract

Objectives: To assess the therapeutic efficacy of cabergoline when given routinely with clomiphene citrate (CC) in infertile women with polycystic ovarian syndrome (PCOS) and normal serum prolactin in single cycle therapy.

Material and methods: This prospective study included a total of 110 infertile women with polycystic ovaries and normal serum prolactin divided into two groups. The first group received only a single cycle clomiphene citrate 100 mg in two divided doses (50 mg × 2) from Day 2 to Day 6. The second group received the same regimen of clomiphene citrate along with cabergoline in two divided doses of 0.5 mg each week at Day 2 and Day 9, respectively. All patients were evaluated through full history and physical examination. Blood was extracted from all patients for hormonal assay and ultrasound for the assessment of ovulation.

Results: The success rate of ovulation induction was statistically significant. Biochemical pregnancy elevated to (36.0%, n = 18) with using combined drugs while it was 14.0%, n = 7, with the use of clomiphene citrate alone (p = 0.011). The clinical pregnancy rate in the study group was elevated to 32.0%, n = 16, which is statistically significant. No significant association was found between abortion and the type of treatment. There were no significant differences between the groups regarding drug side effect like ovarian hyper stimulation rate, multiple pregnancy rate as well as other adverse effects.

Conclusions: Adding cabergoline in small doses together with clomiphene citrate in PCOS infertile women and normal serum prolactin increases the success rate of ovulation & significantly improves pregnancy rate with minimal drug side effects.

Article available in PDF format

View PDF Download PDF file

References

  1. Azziz R, Woods K, Reyna R, et al. The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population. J Clin Endocrinol Metab. 2004; 89(6): 2745–2749.
  2. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41–47.
  3. Belosi C, Selvaggi L, Apa R, et al. Is the PCOS diagnosis solved by ESHRE/ASRM 2003 consensus or could it include ultrasound examination of the ovarian stroma? Hum Reprod. 2006; 21(12): 3108–3115.
  4. Guan H-Y, Zhang W. Huang B-Q. Induction of ovulation with clomiphene citrate combined with pcos with infertility: A prospective randomized controlled clinical trial. Reproductive & Development Medicine. 2017; 4: 216–220.
  5. Papaleo E, Doldi N, De Sa, et al. Cabergoline influences ovarian stimulation in hyper-prolactinaemic patients with polycystic ovary syndrome. Human Reproduction. 2001; 16(11): 2263–2266.
  6. Prelević GM, Würzburger MI, Perić LA. Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome. J Endocrinol Invest. 1987; 10(4): 389–395.
  7. Zahran KM, Mostafa WA, Abbas AM, et al. Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary Syndrome. Middle East Fertility Soc J. 2018; 23(3): 173–177.
  8. Nachtigall LB. Cabergoline for hyperprolactinemia: getting to the heart of it. Endocrine. 2017; 57(1): 3–5.
  9. Hernández I, Parra A, Méndez I, et al. Hypothalamic Dopaminergic Tone and Prolactin Bioactivity in Women with Polycystic Ovary Syndrome. Arch Med Res. 2000; 31(2): 216–222.
  10. Tripathy S, Mohapatra S, M M, et al. Induction of Ovulation with Clomiphene Citrate Versus Clomiphene with Bromocriptine in PCOS Patients with Normal Prolactin: A Comparative Study. J Clin Diagn Res. 2013; 7(11): 2541–2543.
  11. Polson DW, Mason HD, Franks S. Bromocriptine treatment of women with clomiphene-resistant polycystic ovary syndrome. Clin Endocrinol. 1987; 26(2): 197–203.
  12. Elsersy MA. Efficacy of combined cabergoline and metformin compared to metformin alone on cycle regularity in patients with polycystic ovarian disease with hyperprolactinemia: a randomized clinical trial. J Obstet Gynaecol India. 2017; 67(5): 363–369.
  13. Balen A. Polycystic ovarian syndrome and secondary amenorrhea. In: Dewhurst's Textbook of Obstetrics & Gynaecology, Ninth Edition. John Wiley & Sons 2012: 632–652.
  14. Spritzer PM, Motta AB, Sir-Petermann T, et al. Novel strategies in the management of polycystic ovary syndrome. Minerva Endocrinol. 2015; 40(3): 195–212.
  15. Kubota T, Kamada S, Aso T. Combined therapy with bromocriptine and clomiphene citrate for patients with normoprolactinemic amenorrhea. Int J Fertil. 1992; 37(5): 277–282.
  16. Parsanezhad ME, Alborzi S, Jahromi BN. A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptine in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level. Int J Fertil Womens Med. 2002; 47(6): 272–277.
  17. Tripathy S, Mohapatra S, M M, et al. Induction of ovulation with clomiphene citrate versus clomiphene with bromocriptine in PCOS patients with normal prolactin: a comparative study. J Clin Diagn Res. 2013; 7(11): 2541–2543.
  18. Xue T, Li SW, Wang Y. Effectiveness of bromocriptine monotherapy or combination treatment with clomiphene for infertility in women with galactorrhea and normal prolactin: A systematic review and meta-analysis. Curr Ther Res Clin Exp. 2010; 71(4): 199–210.
  19. Mohammadbygi R, Yousefi SR, Shahghaybi S, et al. Effects of cabergoline administration on uterine perfusion in women with polycystic ovary syndrome. Pak J Med Sci. 2013; 29(4): 919–922.